Stock comparison
Halozyme Therapeutics
Bio-Techne
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
TECH
Bio-Techne
Market cap
$7.55B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | TECH | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 55C | HALO |
| Benjamin Graham | 83A | 89A | TECH |
| Philip Fisher | 65B | 50C | HALO |
| Peter Lynch | 53D | 24F | HALO |
| Joel Greenblatt | 40D | 50D | TECH |
| Charlie Munger | 80C | 45D | HALO |
| Terry Smith | 84A | 44D | HALO |
Side-by-side metrics
| Metric | HALO | TECH |
|---|---|---|
| Market cap | $8.1B | $7.55B |
| P/E (TTM) | 24.0x | 61.6x |
| EV/EBIT | 10.2x | 67.1x |
| ROIC (TTM) | 23.65% | 4.75% |
| Gross margin | 81.24% | 64.96% |
| Net margin | 23.13% | 9.05% |
| Revenue CAGR 5y | 33.23% | 6.98% |
| EPS CAGR 5y | -1.98% | -15.23% |
| Debt / Equity | 1.0x | 0.1x |
| Dividend yield | 0.0% | 0.74% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- EPS CAGR 5y-1.98%vs -15.23%+87%
- EV/EBIT10.2xvs 67.1x+85%
- ROIC (TTM)23.65%vs 4.75%+80%
- Revenue CAGR 5y33.23%vs 6.98%+79%
TECH leads on
- Dividend yield0.74%vs 0.0%+100%
- Debt / Equity0.1xvs 1.0x+85%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.